These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 4121701)
1. Chemotactic factor inactivator in normal human serum. Berenberg JL; Ward PA J Clin Invest; 1973 May; 52(5):1200-6. PubMed ID: 4121701 [TBL] [Abstract][Full Text] [Related]
2. Chemotactic factor inactivators of human granulocytes. Brozna JP; Senior RM; Kreutzer DL; Ward PA J Clin Invest; 1977 Dec; 60(6):1280-8. PubMed ID: 334799 [TBL] [Abstract][Full Text] [Related]
3. The relationship of the chemotactic behavior of the complement-derived factors, C3a, C5a, and C567, and a bacterial chemotactic factor to their ability to activate the proesterase 1 of rabbit polymorphonuclear leukocytes. Becker EL J Exp Med; 1972 Feb; 135(2):376-87. PubMed ID: 4551218 [TBL] [Abstract][Full Text] [Related]
9. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. Bokisch VA; Müller-Eberhard HJ; Cochrane CG J Exp Med; 1969 May; 129(5):1109-30. PubMed ID: 5778786 [TBL] [Abstract][Full Text] [Related]
10. Effects of human C 1 inhibitor on complement-mediated human leukocyte chemotaxis. Smith CW; Hollers JC; Bing DH; Patrick RA J Immunol; 1975 Jan; 114(1 Pt 1):216-20. PubMed ID: 1167560 [TBL] [Abstract][Full Text] [Related]
11. C3 leukotactic factors produced by a tissue protease. Hill JH; Ward PA J Exp Med; 1969 Sep; 130(3):505-18. PubMed ID: 4185247 [TBL] [Abstract][Full Text] [Related]
12. Group B streptococci inhibit the chemotactic activity of the fifth component of complement. Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900 [TBL] [Abstract][Full Text] [Related]
13. Chemotactic factor inactivator release from rat leukocytes. Hunt JD; Ward PA Inflammation; 1979 Jul; 3(3):203-14. PubMed ID: 478592 [TBL] [Abstract][Full Text] [Related]
14. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. Perez HD; Lipton M; Goldstein IM J Clin Invest; 1978 Jul; 62(1):29-38. PubMed ID: 659635 [TBL] [Abstract][Full Text] [Related]
15. Role of chemotactic factor inactivator in modulating alveolar macrophage-derived neutrophil chemotactic activity. Robbins RA; Justice JM; Rasmussen JK; Russ WD; Thomas KR; Rennard SI J Lab Clin Med; 1987 Feb; 109(2):164-70. PubMed ID: 3805869 [TBL] [Abstract][Full Text] [Related]
16. Generation of a neutrophil chemotactic agent by spermatozoa: role of complement and regulation by seminal plasma factors. Clark RA; Klebanoff SJ J Immunol; 1976 Oct; 117(4):1378-86. PubMed ID: 977954 [TBL] [Abstract][Full Text] [Related]
17. A unique complement derived chemotactic factor for tumor cells. Romualdez AG; Ward PA Proc Natl Acad Sci U S A; 1975 Oct; 72(10):4128-32. PubMed ID: 172896 [TBL] [Abstract][Full Text] [Related]
18. Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. Kazmierowski JA; Gallin JI; Reynolds HY J Clin Invest; 1977 Feb; 59(2):273-81. PubMed ID: 401834 [TBL] [Abstract][Full Text] [Related]
19. THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO. WARD PA; COCHRANE CG; MUELLER-EBERHARD HJ J Exp Med; 1965 Aug; 122(2):327-46. PubMed ID: 14316948 [TBL] [Abstract][Full Text] [Related]